MYTIL 500 mycophenolate mofetil 500mg tablet blister pack

Држава: Аустралија

Језик: Енглески

Извор: Department of Health (Therapeutic Goods Administration)

Активни састојак:

mycophenolate mofetil, Quantity: 500 mg

Доступно од:

Pharmacor Pty Ltd

INN (Међународно име):

Mycophenolate mofetil

Фармацеутски облик:

Tablet, film coated

Састав:

Excipient Ingredients: povidone; magnesium stearate; microcrystalline cellulose; croscarmellose sodium; hyprolose; purified talc; titanium dioxide; hypromellose; iron oxide red; iron oxide black; macrogol 400; indigo carmine aluminium lake

Пут администрације:

Oral

Јединице у пакету:

150 Tablets, 50 Tablets

Тип рецептора:

(S4) Prescription Only Medicine

Терапеутске индикације:

Prophylaxis of solid organ rejection in adults receiving allogeneic organ transplants. Prophylaxis of organ rejection in paediatric patients (with a body surface area > 1.5 m2) receiving allogeneic renal transplants.

Резиме производа:

Visual Identification: Purple colored, capsule shaped, biconvex, film coated tablets debossed 'AHI' on one side and '500' on other side.; Container Type: Blister Pack; Container Material: PVC/PVDC/Al; Container Life Time: 36 Months; Container Temperature: Store below 25 degrees Celsius

Статус ауторизације:

Licence status A

Датум одобрења:

2015-12-16

Информативни летак

mytil 500 (V 02) Page 1 of 5
MYTIL 500
_Mycophenolate mofetil _
CONSUMER MEDICINE INFORMATION
WHAT IS IN THIS LEAFLET
This leaflet answers some
common questions about Mytil
500.
It does not contain all the
available information.
It does not take the place of
talking to your doctor,
pharmacist.
All medicines have risks and
benefits. Your doctor has weighed
the risks of you taking Mytil 500
against the benefits they expect it
will have for you.
IF YOU HAVE ANY CONCERNS ABOUT
TAKING THIS MEDICINE, ASK YOUR
DOCTOR OR PHARMACIST.
KEEP THIS LEAFLET WITH THE
MEDICINE
You may need to read it again.
WHAT MYTIL 500 IS USED FOR
Mytil 500 contains the active
ingredient
mycophenolate mofetil.
Mytil 500 belongs to a group of
medicines called
immunosuppressants.
Immunosuppressants are used to
prevent the rejection of a
transplanted organs and work by
stopping your immune system
from reacting to the transplanted
organ.
There are many different types of
medicines used to prevent
rejection of a transplanted organ
MytilMytil 500 may be used
together with other medicines
known as cyclosporin and
corticosteroids.
ASK
YOUR
DOCTOR
IF
YOU
HAVE
ANY
QUESTIONS ABOUT WHY MYTIL 500 HAS
BEEN PRESCRIBED FOR YOU.
Your doctor may have
prescribed Mytil 500 for another
reason.
Pharmacor
Mycophenolate
500
is
not addictive
This medicine is available only with a
doctor’s prescription.
Mytil
BEFORE YOU TAKE MYTIL 500
_WHEN YOU MUST NOT TAKE IT _
DO NOT TAKE MYTIL 500 IF:
1.
YOU HAVE HAD AN ALLERGIC
TO:
Mytil 500 or any ingredients
listed at the end of this leaflet.
Some of the symptoms of an
allergic reaction may include:

shortness of breath

wheezing
or
difficulty
breathing

swelling of face, lips,
tongue or other parts of
the body

rash, itching, hives on the
skin
2. YOU ARE PREGNANT

Mytil 500 is harmful to an
unborn baby when taken
by a pregnant woman.

There have been cases of
miscarriage and severe
birth defects reported
when patients have taken
Mytil 500 during
pregnancy.

You must tell your doctor if
you are pregnant or

Карактеристике производа

MYTIL 500 (V-02)
1
AUSTRALIAN PRODUCT INFORMATION
MYTIL 500 (MYCOPHENOLATE MOFETIL) TABLETS
1
NAME OF THE MEDICINE
Mycophenolate mofetil
2
QUALITATIVE AND QUANTITATIVE COMPOSITION
Mytil 500 contains mycophenolate mofetil 500 mg.
For the full list of excipients, see Section 6.1 List of excipients.
3
PHARMACEUTICAL FORM
Mytil 500 are purple coloured, capsule shaped, biconvex, film coated
tablets debossed ‘AHI’
on one side and ‘500’ on other side.
4
CLINICAL PARTICULARS
4.1
T
HERAPEUTIC INDICATIONS

Prophylaxis of solid organ rejection in adults receiving allogeneic
organ transplants.

Prophylaxis of organ rejection in paediatric patients (2-18 years)
receiving allogeneic
renal transplants.
4.2
D
OSE AND METHOD OF ADMINISTRATION
The
initial
dose
of
Mytil
500
should
be
given
as
soon
as
clinically
feasible
following
transplantation. Intravenous administration is recommended in those
patients unable to
take oral medication. However, oral administration should be initiated
as soon as possible.
ADULTS
_RENAL TRANSPLANTATION _
The
recommended
dose
in
renal
transplant
patients
is
1
g
administered
orally
or
intravenously twice daily (2 g daily dose).
_CARDIAC TRANSPLANTATION _
The recommended dose in cardiac transplant patients is 1.5 g
administrated orally or
intravenously twice daily (3 g daily dose).
_HEPATIC TRANSPLANTATION _
The recommended dose in hepatic transplant patients is 1 g
administrated intravenously
twice daily (2 g daily dose) followed by 1.5 g administered orally
twice daily (3 g daily dose).
MYTIL 500 (V-02)
2
_OTHER TRANSPLANTS _
The recommended dose in other transplants is 2 to 3 g per day
depending on the level of
immunosuppression required.
_PAEDIATRICS (2 TO 18 YEARS) _
The recommended dose of for renal transplant patients is 600mg/m
2
of mycophenolate
mofetil (MMF) administered orally twice daily (up to a maximum of 2 g
daily.)
Mytil 500 may be administered in combination with cyclosporin and
corticosteroids.
COMPLETE
BLOOD
COUNTS
SHOULD
BE
PERFORMED
WEEKLY
DURING
THE
FIRST
MONTH,
TWIC